secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protagenic Therapeutics, Inc.new (PTIX)
CIK:        0001022899
Form:       8-K
Filed at:   2024-09-18T23:59:59+00:00
Accession:  0001493152-24-036925
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Protagenic Therapeutics updates PT00114 milestones: Phase I multi-dose Q4 2024, Phase IIa Q3 2025
--------------------------------------------------------------------------------

- Multiple dose portion of Phase I study for PT00114 expected to commence Q4 2024.
- Results from multiple dose portion of Phase I study for PT00114 expected Q2 2025.
- Initiation of Phase IIa study for PT00114 expected Q3 2025.
- Company will provide further updates to clinical development schedule as it becomes clearer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1022899/000149315224036925/0001493152-24-036925-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1022899/000149315224036925/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-036925

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer